A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Summary

This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.

Timeline

Start

2023-09-15

Primary completion

2024-02-07

Completion

2024-02-19

Outcome

Mixed primary results

registry analysis (superiority test); Placebo to K-757 and K-833 vs K-757 Alone; p = 0.0756 NCT06019559 ↗

registry LEAST_SQUARES_MEAN K-757 Alone: -1.57 (Standard Error 0.566) % Change from Baseline NCT06019559 ↗

registry analysis (superiority test); Placebo to K-757 and K-833 vs K-757+K-833; p = 0.0008 NCT06019559 ↗

registry LEAST_SQUARES_MEAN K-757+K-833: -2.94 (Standard Error 0.587) % Change from Baseline NCT06019559 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	K-757	Unknown	120 mg	Oral
Subject	K-833	Unknown	100 mg	Oral

Indications